Abnormal expression of PI3K isoforms in patients with tobacco-related oral squamous cell carcinoma

Richa Garg1, Vaishali Kapoor, Manasi Mittal

  • 1Department of Biotechnology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029, India.

Abstract

Insights

Circulating phosphatidylinositol 3-kinase (PI3K) p110α is upregulated in oral squamous cell carcinoma (OSCC). Higher levels correlate with tumor progression, suggesting PI3K p110α as a prognostic marker for OSCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Phosphatidylinositol 3-kinase (PI3K) signaling pathways are crucial for cellular functions including proliferation and survival.
  • Dysregulation of PI3K signaling is implicated in various cancers.
  • Limited data exists on PI3K isoform expression in oral cancer.

Purpose of the Study:

  • To investigate the expression of various PI3K isoforms in oral squamous cell carcinoma (OSCC).
  • To determine the potential of PI3K isoforms as biomarkers for tobacco-related OSCC.

Main Methods:

  • Studied PI3K isoforms (p110α, p110γ, PI3K-C2, Vps34p, p85α) in tumor tissues and peripheral blood mononuclear cells (PBMCs) from 108 OSCC patients and 46 controls.
  • Utilized RT-qPCR for mRNA expression analysis.
  • Measured serum PI3K p110α levels using Surface Plasmon Resonance (SPR) and ELISA.

Main Results:

  • Significantly higher PI3K p110α mRNA and lower Vps34p mRNA were observed in OSCC patients' PBMCs and tissues compared to controls.
  • Elevated circulating PI3K p110α levels were detected in OSCC patients.
  • SPR data revealed a direct correlation between PI3K p110α levels and advancing disease stage.
  • PI3K p110α overexpression was specific to tumor samples, not normal buccal mucosa.

Conclusions:

  • Upregulation of circulating PI3K p110α isoform in OSCC patients correlates with tumor burden.
  • PI3K p110α may serve as a significant prognostic indicator for tobacco-related OSCC.
  • PI3K p110α represents a potential therapeutic and chemo-preventive target for OSCC.